Pure Global AI
NCT06135909Not yet recruiting

CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy, CHASE Study

CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary Hypertension Using Targeted Therapy
Chinese Pulmonary Vascular Disease Research GroupClinicalTrials.gov
Verified
Study focus
Disease/Condition
Pulmonary Hypertension
Study type
Observational
Sponsor & location
Primary sponsor
Chinese Pulmonary Vascular Disease Research Group
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2023
End date
Dec 31, 2027
Enrollment
5000 participants
Primary outcome

Incidence of clinical worsening events 1 year after enrollment

Summary

CHina Registry for the chAracteristics and Management strategieS of patiEnts With Pulmonary
 Hypertension Using Targeted Therapy (CHASE Study)

ICD-10 classifications
Primary pulmonary hypertensionOther secondary pulmonary hypertensionPulmonary heart disease and diseases of pulmonary circulationPulmonary heart disease, unspecifiedPulmonary valve disorders
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06135909
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06135909 through Pure Global AI's free database. This phase not specified trial is sponsored by Chinese Pulmonary Vascular Disease Research Group and is currently Not yet recruiting. The study focuses on Pulmonary Hypertension. Target enrollment is 5000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.